G
Gabriel Raggio
Researcher at Bristol-Myers Squibb
Publications - 11
Citations - 1428
Gabriel Raggio is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Population & Type 2 diabetes. The author has an hindex of 10, co-authored 11 publications receiving 1409 citations.
Papers
More filters
Journal ArticleDOI
The impact of compliance with osteoporosis therapy on fracture rates in actual practice
TL;DR: It is indicated that improving compliance in actual practice may significantly decrease osteoporosis-related fracture risk and this association was maintained within subgroups and after controlling for other patient characteristics that independently predict the fracture rate.
Journal Article
Persistence with treatment for hypertension in actual practice
TL;DR: Analysis of actual practice data indicates that barriers to persistence occur early in the therapeutic course and that achieving successful therapy when treatment is started is important to maintaining long-term persistence.
Journal Article
Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data
TL;DR: A relation not seen in clinical trials--between persistence with treatment and initial antihypertensive medication prescribed--was found in actual practice, indicating the importance of real-world studies for evidence-based medicine.
Journal ArticleDOI
Direct medical costs of complications resulting from type 2 diabetes in the U.S.
TL;DR: The cost estimates from this study provide one piece of the economic analysis needed to evaluate new interventional therapies that may reduce the incidence of some diabetic complications and need to be scrutinized economically in today's cost-conscious environment.
Journal ArticleDOI
Assessment of health economics in Alzheimer’s disease (AHEAD) based on need for full-time care
TL;DR: The AHEAD model provides a relatively simple framework for the prediction of time to FTC requirement based on short-term observed data such as those from clinical trials, and provides a standard estimation technique that may facilitate comparisons between existing and emerging therapies.